Navigation Links
TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
Date:12/6/2007

SAN DIEGO, Dec. 6 /PRNewswire/ -- TargeGen, Inc. today announced that the Company's recently submitted IND for TG101348 is now active and the Company plans to initiate a multi-center clinical trial of TG101348, an internally discovered, oral, potent, and highly selective JAK2 inhibitor in January, 2008. Additionally, TargeGen announced that a series of presentations related to TG101348 will be made at the 2007 ASH Conference (Atlanta, December 8-11, 2007) by Company scientific staff and outside academic collaborators.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)

Scheduled ASH presentations include:

-- Catriona Jamieson -- Selective Inhibition of JAK2 Driven Erythroid

Differentiation of Polycythemia Vera

-- Animesh Pardanani & Ayalew Tefferi -- Primary Cell Experiments with

TG101348, A JAK2 Selective Small Molecule Inhibitor, in the Presence of

Myeloproliferative Disorder-Associated JAK2V617F, MPLW515K, or Exon 12

Mutations

-- Gerlinde Wernig & Gary Gilliland -- Efficacy of TG101348, a Selective

JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced

Polycythemia Vera, Session Type

-- Betty Tam -- TG101348: A Dual Acting JAK2/FLT3 Small Molecule Kinase

Inhibitor for the Treatment of AML

-- John Hood -- Prospective Identification of Resistance Mutants to the

JAK2 Inhibitor TG101348

The V617F mutation of JAK2 is implicated in the pathogenesis of certain myeloproliferative diseases, including polycythemia vera (PV), essential thrombocytopenia (ET) and primary myelofibrosis (PMF). In preclinical models of myeloproliferative diseases, TG101348, administered orally, was shown to reduce to reduce V617F expressing cell populations in a dose-dependant manner without adversely impacting normal hematopoeisis. The reduction of V
'/>"/>

SOURCE TargeGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 3, 2015 ... adquisición del 100% de participación en ZAO "Biocom" ... adquisición marca la incursión de Lupin en el ... de RUB en ventas, colocándolo como uno de ... 2014 (IMS Health). Durante más de una década, ...
(Date:7/2/2015)... CHAPEL HILL, N.C. , July 2, 2015 ... their own employees to capture critical product and ... there are many benefits to employee-based studies, it ... to leverage their own internal employees to capture ... recent study by benchmarking firm, Best Practices, LLC, ...
(Date:7/2/2015)... , July 2, 2015 ResMed Inc. (NYSE: ... quarter and fiscal year ended June 30, 2015 results on ... market close. A press release with ResMed,s results will be ... will host a webcast to discuss operating results and future ... at 1:30 p.m. US Pacific Time and the live webcast ...
Breaking Medicine Technology:Lupin adquiere Biocom en Rusia 2Lupin adquiere Biocom en Rusia 3Leveraging Employee Insights to Produce Cutting-Edge Market Research 2ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2
... IRVINE, Calif., Nov. 5 Masimo (Nasdaq: ... Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that ... Inhalation Toxicology demonstrates that Masimo Rainbow ... measurements of carbon monoxide (CO) in the blood that ...
... 5 Amgen (Nasdaq: AMGN ) today announced ... (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) ... failed to meet a secondary endpoint of overall survival. ... trial met its primary endpoint by significantly prolonging progression-free ...
Cached Medicine Technology:New Published Study Shows Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Reliably Determines Carbon Monoxide Levels in the Blood 2New Published Study Shows Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Reliably Determines Carbon Monoxide Levels in the Blood 3New Published Study Shows Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Reliably Determines Carbon Monoxide Levels in the Blood 4New Published Study Shows Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Reliably Determines Carbon Monoxide Levels in the Blood 5Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 2Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 3Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 4Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 5Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 6Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 7Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 8
(Date:7/3/2015)... ... ... Jennifer Renee Hanes, DO is the new Medical Director of its Sienna ... freestanding emergency rooms in the United States. , “We are excited to welcome Dr. ... Medical Director of First Choice Emergency Room, Dr. James M. Muzzarelli. , Dr. ...
(Date:7/3/2015)... , ... July 03, 2015 , ... Yisrayl Hawkins, Pastor ... article this week that he says will reveal biblical truth and expose popular lies ... Does Your Bible Say Don’t Have Sex”, immediately goes into the core of the ...
(Date:7/2/2015)... Richmond, VA (PRWEB) , ... July 02, 2015 , ... ... New Albany, Mississippi. The opening is the first sweetFrog store located in Mississippi. The ... fastest growing companies in 2014. , The store, located at 104 Railroad Avenue, New ...
(Date:7/2/2015)... ... ... Following the recent report by JAMA Internal Medicine published on June ... Becic emphatically declared a war on obesity in the United States. , "Obesity is ... understand the magnitude of this discovery. For that reason, I am declaring, along with ...
(Date:7/2/2015)... Lincoln, RI (PRWEB) , ... July 02, 2015 , ... ... keep safety in mind. That’s why Amica Insurance is sharing some tips ... Safety Commission (CPSC), approximately 230 people go to the emergency room daily with fireworks-related ...
Breaking Medicine News(10 mins):Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetfrog Opens First Location in Mississippi 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:6 Fireworks Safety Tips from Amica Insurance 2
... N.C. Common foot disorders such as flat feet, corns and ... new study by University of North Carolina at Chapel Hill researchers ... older were three times more likely than whites of the same ... In people who were not obese, African Americans were twice as ...
... is available in French . , A fundamental ... doctors who treat breast cancer, this is easier said than ... breast cancer their treatment usually involves surgery to remove ... cancer returning. But studies show that for most patients with ...
... HealthDay Reporter , MONDAY, Nov. 8 (HealthDay News) ... moms must make in order to breast-feed is their sleep. ... The study, published online Nov. 8 in the journal ... same amount of time whether they were breast-feeding or formula-feeding. ...
... outlook for patients with breast cancer is determined in part ... sites in the body. A team of researchers, led by ... Compostela, Spain, has now identified in a subset of patients ... tumors at distant sites; a finding that they hope might ...
... amount of bleeding in the brain seems to be ... study. Neurologist Dr. Mark Fisher and neuropathologist Dr. ... in the aging brain and not primarily products ... Alzheimer,s, as had been thought. "Prior work relied ...
... joint pain from taking aromatase inhibitors (AIs) if they have ... American College of Rheumatology,s annual meeting, held Nov. 7-11, in ... factors that increase the likelihood that a patient will suffer ... therapy for post-menopausal breast cancer, can cause joint pain in ...
Cached Medicine News:Health News:Frequency of foot disorders differs between African-Americans and whites 2Health News:Breast cancer: Reducing the risk of unnecessary chemo 2Health News: Breast-Feeding Won't Rob Mom of Sleep: Study 2Health News: Breast-Feeding Won't Rob Mom of Sleep: Study 3Health News:Study sheds light on aromatase inhibitor joint pain syndrome 2Health News:Study sheds light on aromatase inhibitor joint pain syndrome 3
... 1 enables hospitals to ... monitors to a single ... temperature monitoring disposale probes ... superior in their manufacture ...
... Level 1 enables ... multiparameter patient monitors to ... series. Our temperature monitoring ... cables are superior in ...
... The bodys warmth beneath drapes. The life-giving ... are yours to guard, measure, stabilize and ... products helps you do your job, giving ... most comfortable and precise management of your ...
... heartbeat. The bodys warmth beneath drapes. The ... signs are yours to guard, measure, stabilize ... Monitoring products helps you do your job, ... the most comfortable and precise management of ...
Medicine Products: